Non-invasive tests for Morquio A
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial studies Morquio A (MPS IVA) using non-invasive ways to measure how the body is working, and to better understand why the condition happens. If you have Morquio A, this may help researchers learn more and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Morquio A (also called MPS IVA).
- Your Morquio A diagnosis must be confirmed by a blood or white blood cell enzyme test showing less than 5% of normal enzyme activity.
- You likely need to provide proof/results of that enzyme test for screening.
- There are no listed exclusion criteria, so other health issues (beyond Morquio A confirmation) are not stated here.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at heart structure and function in people with mucopolysaccharidosis (MPS), a rare genetic disorder. It aims to understand how MPS affects the heart over time.
This study follows people with rare genetic conditions (GM1, GM2, sialidosis, or galactosialidosis) that affect how the body breaks down certain substances in cells. Researchers track how these diseases progress to better understand them and potentially help future patients.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
This study follows people with MPS IIIC (Sanfilippo syndrome type C) over time to understand how the disease changes. It does not test a new treatment, but helps researchers learn more about the condition, which could lead to better care in the future.
Hear when a new MPS IVA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.